Abiraterone acetate

본문 바로가기


Home > Product > Abiraterone acetate
Selling leads
Abiraterone acetate
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Abiraterone acetate was initially developed through a collaboration between Cancer Research UK and BTG. Later, the global development rights and marketing rights were transferred to Cougar Biopharmaceuticals in the United States (now a subsidiary of Johnson & Johnson). Abiratone acetate was first approved for marketing in the United States on April 28, 2011, under the trade name Zytiga. It is an oral tablet with a dosage of 250mg and is used in combination with prednisone to treat castration-resistant prostate cancer (cRPC) whose disease progression cannot be controlled by docetaxel.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top